Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

NCT06821191 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: clopidogrel 75 mg
DRUG: Prasugrel 5 mg

Sponsor

University of Florida